血液腫瘍患者に対するがん化学療法における薬学的ケアの臨床的有用性

概要

論文の詳細を見る
In cancer chemotherapy, avoidance of adverse effects, improvement of quality of life (QOL) and palliative care are clinically important types of supportive therapy. The aim of this study was to clarify the clinical usefulness of pharmaceutical care in cancer chemotherapy and to do this a survey of thirty-five patients with malignant hematological diseases was conducted from March 2005 to August 2005 at the Social Insurance Kyoto Hospital. The survey revealed that there had been 35 cases in which pharmaceutical intervention had been proposed in 15 patients. Interventions related to chemotherapy protocols accounted for 8.6% of the total (3/35 cases) while the remaining 91.4% related to supportive therapy of which prescription changes accounted for 40.0% (14 patients). Among the 35 cases of proposed prescription changes, 27 (77.1%) were accepted. They comprised 14 cases of measures to avoid adverse effects, 3 cases of supportive therapy to improve QOL, 3 cases of palliative care and 7 cases relating to optimum dosages. Supportive therapy to directly mitigate the adverse events of cancer chemotherapy thus accounted for 20 cases of intervention (74.1%). In 24 of the 27 cases of prescription changes (88.9%), adverse effects were avoided or there was an improvement in symptoms. Our findings show that pharmaceutical care functions well in supportive therapy, and is clinically useful in cancer chemotherapy.
日本医療薬学会の論文
2007-11-10